Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, particularly Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury (mTBI). The Alpha Cognition news feed on Stock Titan aggregates company announcements, clinical updates, and capital markets disclosures so readers can follow how its Alzheimer’s and neuroscience programs progress over time.
News for ACOG frequently centers on the commercialization of ZUNVEYL, an FDA-approved new-generation acetylcholinesterase inhibitor for mild to moderate Alzheimer’s dementia in adults. Company releases describe launch momentum in the U.S. long-term care channel, including growth in pharmacy orders, expansion of the prescriber base, and increasing penetration into nursing homes. Updates also cover payer coverage developments, such as additional pharmacy benefit manager contracts, and the company’s efforts to deepen relationships with long-term care facilities.
Investors and healthcare observers will also find coverage of clinical and real-world evidence studies involving ZUNVEYL and ALPHA-1062, including planned and ongoing studies in Alzheimer’s disease patients in long-term care settings and research on cognitive impairment following traumatic brain injury. Alpha Cognition regularly reports on scientific presentations at meetings like the American Society of Consultant Pharmacists and the Neuroscience Education Institute, where it shares data on cholinesterase inhibitors, treatment persistence, and patient outcomes.
In addition, the ACOG news stream includes financing transactions, such as public offerings and at-the-market programs, licensing agreements for ZUNVEYL in Asia, and SEC-reportable events like changes in auditors or stock incentive plans. By reviewing this page, readers can track how Alpha Cognition’s commercial execution, clinical data, and corporate actions evolve, all in one consolidated news hub.
Alpha Cognition (Nasdaq: ACOG), a biopharmaceutical company focused on neurodegenerative disease treatments, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 31, 2025, after market close.
The company will host a conference call at 4:30pm ET to discuss financial and operating results. Investors can participate via phone (1-877-407-9039 or 1-201-689-8470) or through a live audio webcast. A Call me™ feature is available to avoid operator wait times, and an audio replay will be accessible through provided contact numbers and access ID: 13752398.
Alpha Cognition (Nasdaq: ACOG) has officially launched ZUNVEYL (Benzgalantamine), the first FDA-approved oral treatment for mild to moderate Alzheimer's disease in the past decade. The company has deployed a 32-person sales team targeting the $2 billion Long-Term-Care market.
The commercial team, averaging 16 years of industry sales experience and 10 years in long-term care, is now actively engaging with healthcare providers nationwide. ZUNVEYL is available in three doses (5 mg, 10 mg, and 15 mg) through pharmacies across the country.
Lauren D'Angelo, Chief Operating Officer and Chief Commercial Officer, emphasized that all launch activities were delivered on-time and on-budget, positioning ZUNVEYL for success in providing a differentiated treatment option for Alzheimer's patients.
Alpha Cognition (NASDAQ: ACOG) has been granted a new patent by the USPTO titled 'Coated Tablets for pH-Dependent Release of Benzgalantamine.' The patent strengthens the company's intellectual property portfolio by protecting tablet formulations of benzgalantamine, extending ZUNVEYL's patent protection in the United States through 2044.
ZUNVEYL, a novel treatment for mild to moderate Alzheimer's disease, is designed to improve patient outcomes through optimized drug delivery. The company plans to launch ZUNVEYL in U.S. pharmacies in Q1 2025, where it will be available by prescription nationwide.
Alpha Cognition Inc. (NASDAQ: ACOG) has achieved significant milestones in 2024, including FDA approval for its Alzheimer's therapy ZUNVEYL (benzgalantamine), a successful $4.5M financing round, and NASDAQ listing preparations. The company is positioned to launch ZUNVEYL in Q1 2025, with sales force and commercial production already in place.
ZUNVEYL targets the long-term care (LTC) market, which represents a $2 billion addressable market and 36% of Alzheimer's prescriptions. The drug's prodrug mechanism improves patient outcomes by reducing common side effects like nausea and insomnia. Additionally, Alpha Cognition has secured a $44M licensing agreement with China Medical Systems Holdings.
Alpha Cognition (NASDAQ: ACOG) has announced strategic appointments to strengthen its commercial and medical teams ahead of the ZUNVEYL launch, its treatment for mild to moderate Alzheimer's disease, planned for Q1 2025. The company has appointed:
- Jen Pesa as VP of Commercial, bringing 25 years of pharmaceutical experience and 12 successful product launches
- Jack Kelly as Head of Market Access, with 30+ years in pharmaceutical industry
- Rommel Fernandez as VP of Corporate Strategy and Operations, with 17 years of experience in pharma and biotech
- Kurt Grady as VP of Medical Affairs, bringing 30 years of healthcare experience
These appointments aim to build the commercial infrastructure necessary for ZUNVEYL's nationwide pharmacy launch, with particular focus on the long-term care (LTC) segment.
Alpha Cognition (ACOG) has entered into a $44 million exclusive licensing agreement with China Medical System Holdings for ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia, and New Zealand. The agreement includes $6 million in upfront payments plus development and commercial milestone payments, along with royalties on net sales.
ZUNVEYL, an FDA-approved oral treatment for mild-to-moderate Alzheimer's disease, will be developed, manufactured, and commercialized by CMS in the licensed territories. The target market includes an estimated 50 million people with Alzheimer's disease in the region. Alpha Cognition maintains its plans for a U.S. launch in Q1 2025.
Alpha Cognition (ACOG) has announced an investor update call scheduled for January 28th, 2025, at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), their FDA-approved treatment for mild-to-moderate Alzheimer's disease. The presentation will focus on addressing the $2 billion U.S. long-term care market.
ZUNVEYL is notably only the second oral Alzheimer's treatment approved in over a decade. The call will feature presentations from the company's leadership team, including CEO Michael McFadden and COO/CCO Lauren D'Angelo, alongside key thought leaders Dr. Hany Mohamed and Cathy Parker, who bring extensive experience in long-term care settings.
The presentation will cover market positioning, launch strategy, and long-term growth objectives for the Q1 2025 commercial launch.
Alpha Cognition (Nasdaq: ACOG) announced that underwriters have partially exercised their over-allotment option to purchase an additional 488,506 common shares at US$5.75 per share, generating US$2.8 million in additional gross proceeds. Following this exercise, the company's total offering reached 9,184,159 shares, raising approximately US$52.8 million in gross proceeds before deducting expenses.
The company's shares began trading on The Nasdaq Capital Market on November 12, 2024, under ticker ACOG. Proceeds will fund ZUNVEYL™ commercialization for Alzheimer's Disease, pipeline product development, commercial CMC activities, and working capital. Titan Partners Group is serving as Sole Bookrunner for the offering.
Alpha Cognition (NASDAQ: ACOG) has announced its voluntary delisting from the Canadian Securities Exchange (CSE), effective at the close of trading on December 17, 2024. The company's common shares will continue to trade exclusively on the Nasdaq Capital Market under the symbol 'ACOG'. This decision comes in connection with the company's existing Nasdaq listing.
Alpha Cognition (ACOG) announced positive interim preclinical data for ALPHA-1062 in treating mild traumatic brain injury (mTBI), specifically focusing on blast trauma injuries relevant to military personnel. The study, conducted in collaboration with the Seattle Institute of Biomedical and Clinical Research and supported by the US Department of Defense, showed promising results in a rodent model.
The interim data revealed that ALPHA-1062 administration following three consecutive days of blast-induced mTBI reduced neuroinflammation markers and neuropathology. High doses demonstrated reduced myeloid cell activation across multiple brain regions and decreased midbrain astrogliosis one month after blast. Final study results, including neuropathology and neurobehavioral data analysis, are expected in Q2/2025.